A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, Eduardo, Litvan, Irene, Höglinger, Günter U., Burn, David, Lees, Andrew, Andrés, María V., Gómez‐Carrillo, Belén, León, Teresa +2 more·2014·Movement Disorders
DOI 10.1002/mds.25824

Cited by (326)

Items 201–300 of 326

  1. PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport
    Paraskevi Tziortzouda, Jolien Steyaert, Wendy Scheveneels, Adrià Sicart, Katarina Stoklund Dittlau, Adriana Margarida Barbosa Correia, Thibaut Burg, Arun Pal, Andreas Hermann, Philip Van Damme et al. · 2024 · Acta Neuropathologica
  2. Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy
    Nastaran Karimi, Feyza Bayram Catak, Ebru Ozturk Arslan, Amene Saghazadeh, Nima Rezaei · 2022 · International Immunopharmacology
  3. Alzheimer's disease research in Ibero America
    Heather M. Snyder, María del Carmen Cárdenas‐Aguayo, Alejandra del C. Alonso, Lisa J. Bain, Khalid Iqbal, María C. Carrillo · 2016 · Alzheimer s & Dementia
  4. In vivo dynamics of hard tissue-forming cell origins: Insights from Cre/loxP-based cell lineage tracing studies
    Toshihide Mizoguchi · 2024 · Japanese Dental Science Review
  5. Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)
    Swanand Vinayak Joshi, Devandla Soujanya, Manchella Sai Supriya, Venkata Madhavi Yaddanapudi, Srinivas Nanduri · 2025 · Expert Opinion on Therapeutic Patents
  6. New routes in frontotemporal dementia drug discovery
    Laura De Conti, Barbara Borroni, Marco Baralle · 2017 · Expert Opinion on Drug Discovery
  7. The pivotal role of glycogen synthase kinase 3 (GSK-3) in vomiting evoked by specific emetogens in the least shrew (Cryptotis parva)
    W. Zhong, Nissar A. Darmani · 2019 · Neurochemistry International
  8. LC–MS/MS determination of tideglusib, a novel GSK-3β inhibitor in mice plasma and its application to a pharmacokinetic study in mice
    Neeraj Kumar Saini, Suresh Ponnayyan Sulochana, Mahalakhsmi Lella, Ravi Kanth Bhamidipati, Sriram Rajagopal, Ramesh Mullangi · 2017 · Journal of Pharmaceutical and Biomedical Analysis
  9. Sex differences for cognitive decline in progressive supranuclear palsy
    Leonardino A. Digma, Irene Litvan, Teodoro del Ser, Ece Bayram · 2023 · Parkinsonism & Related Disorders
  10. Tideglusib Ameliorates Ischemia/Reperfusion Damage by Inhibiting GSK-3β and Apoptosis in Rat Model of Ischemic Stroke
    Balu Joshi, Devendra Singh, Himika Wasan, Uma Sharma, K.H. Reeta · 2022 · Journal of Stroke and Cerebrovascular Diseases
  11. Diabetic Endothelial Cell Glycogen Synthase Kinase 3β Activation Induces VCAM1 Ectodomain Shedding
    Masuma Akter Brishti, Somasundaram Raghavan, Kennedy Lamar, Udai Pratap Singh, Daniel Mohr Collier, Marie Dennis Leo · 2023 · International Journal of Molecular Sciences
  12. Dynamics of microtubules and their associated proteins
    Eduardo Elias Benarroch · 2016 · Neurology
  13. Focusing on oligomeric tau as a therapeutic target in Alzheimer’s disease and other tauopathies
    Joseph B. Rayman · 2023 · Expert Opinion on Therapeutic Targets
  14. Alzheimer’s Disease and Dementia
    Patrick Alfryn Lewis, Jennifer E. Spillane · 2018 · Elsevier eBooks
  15. Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
    Tridente, Giuseppe, Jana, Ankit, Nath, Arnab, Ashraf, Ghulam Md · 2023 · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders
  16. Prospective Multicenter Evaluation of the MDS “Suggestive of PSP ” Diagnostic Criteria
    Andrea Quattrone, Nicolai Franzmeier, Johannes Levin, Gabor C. Petzold, Annika E. Spottke, Frederic Brosseron, Björn H. Falkenburger, Johannes Prudlo, Thomas Gasser, The DESCRIBE‐PSP Group, The ProPSP Group et al. · 2025 · Movement Disorders
  17. Disease-modifying vs symptomatic treatments: Splitting over lumping
    Kevin R. Duque, Joaquín A. Vizcarra, Emily J. Hill, Alberto Javier Espay · 2023 · Handbook of clinical neurology
  18. The regenerative potential of Tideglusib and CHIR99021 small molecules as potent odontogenic differentiation enhancers of human dental pulp stem cells
    Samer Hanna, Ghada Nour Eldeen, Ruth Pérez Alfayate, Riham Mohammed Aly · 2023 · Clinical Oral Investigations
  19. Robust and predictive 3D-QSAR models for predicting the activities of novel oxadiazole derivatives as multifunctional anti-Alzheimer agents
    Yekai Sun, Zirou Zhang, Menghao Wen, Fangfang Wang, Xiuling Li, Wei Yang, Bo Zhou · 2024 · RSC Advances
  20. Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy
    Brent Bluett, Irene Litvan · 2015 · Expert Opinion on Orphan Drugs
  21. Tauopathien
    Gábor Géza Kovács, Gesine Respondek, Thilo van Eimeren, E Holler, Johannes Levin, Ulrich Müller, Sigrid C. Schwarz, Thomas W. Rösler, Kerstin Schweyer, Günter U. Höglinger · 2018 · Der Nervenarzt
  22. Small Molecular Immune Modulators as Anticancer Agents
    Yongxin Han, Li Zhu, Wei Wu, Hui Zhang, Wei Hu, Liguang Dai, Yanqing Yang · 2020 · Advances in experimental medicine and biology
  23. Production and Commercialization Status of Improved Panicum Grass Cultivation in the Lowland Livestock Production System of South Omo South-Western Ethiopia
    Denbela Hidosa, Asmera Adicha, Muhaba Sultan · 2022 · Research on World Agricultural Economy
  24. Disease‐Modifying Treatments for Progressive Supranuclear Palsy
    María Stamelou, Adam L. Boxer · 2015 · Movement Disorders Clinical Practice
  25. Protein levels in Keap1-Nrf2 system in human failing heart
    Masaaki Konishi, Anna Baumgarten, Junichi Ishida, Masakazu Saitoh, Stefan D. Anker, Jochen Springer · 2016 · International Journal of Cardiology
  26. GSK-3 Inhibitors: From the Brain to the Retina and Back Again
    Alonso Sánchez-Cruz, Ana Martı́nez, Enrique J. de la Rosa, Catalina Hernández‐Sánchez · 2019 · Advances in experimental medicine and biology
  27. Deciphering phosphorylation TACtics: Advances in phosphorylation targeting strategies and bifunctional modalities
    Dong-Ting Ke, Zilong Zhan, Wenliang Zhang, Zhenyi Hu, Po‐Han Chen · 2026 · Cell chemical biology
  28. Investigational therapeutics for the treatment of progressive supranuclear palsy
    David G. Coughlin, Irene Litvan · 2022 · Expert Opinion on Investigational Drugs
  29. Serine/Threonine Protein Phosphatase 2A Regulates the Transport of Axonal Mitochondria
    Keunjung Heo, Himanish Basu, Amos Gutnick, Wei Wei, Evgeny Shlevkov, Thomas L. Schwarz · 2022 · Frontiers in Cellular Neuroscience
  30. Molecular Pathways Governing the Termination of Liver Regeneration
    Lianne R. de Haan, Rowan F. van Golen, Michal Heger · 2024 · Pharmacological Reviews
  31. The duality of GSK-3β in urinary bladder cancer: Tumor suppressor and promoter roles through multiple signaling pathways
    Zufa Sabeel, Jianfeng Wang, Jian Dong, Yan Liu, Changyuan Yu, Yang Zhao · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  32. Barcelona Progressive Supranuclear Palsy ( PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases
    Cèlia Painous, Manel Fernández, Ana Cámara, Salut Albà-Arbalat, Marta Soto, Carla Brenlla, Esteban Muñoz, Alexandra Pérez‐Soriano, Francesc Valldeoriola, Marı́a José Martı́ et al. · 2025 · Movement Disorders
  33. Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia
    Kadriye Nehir Cosgun, Huda Jumaa, Mark E. Robinson, Zhangliang Cheng, Salim Oulghazi, Kohei Kume, David Fonseca Arce, Nikol Agadzhanian, Klaus M. Kistner, Etienne Léveillé et al. · 2026 · Nature Cancer
  34. Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory
    Mohamed Gewily, Elodie L. Plan, Elham Yousefi, Franz König, Martin Posch, Franziska Hopfner, Günter U. Höglinger, Mats O. Karlsson · 2024 · Movement Disorders
  35. Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
    Reyaz Hassan Mir, Mubashir Hussain Masoodi, Abdul Jalil Shah, Roohi Mohi-ud-din, Saba Sabreen, Taha Umair Wani, Rafia Jan, Md. Noushad Javed, Prince Ahad Mir · 2022 · Current Molecular Pharmacology
  36. GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
    Sorin Hostiuc, Paula Perlea, Mihai Marinescu, Cătălin Dogăroiu, Eduard Polea Drima · 2019 · Frontiers in Pharmacology
  37. Emerging drugs for progressive supranuclear palsy
    Nikolaos Giagkou, María Stamelou · 2019 · Expert Opinion on Emerging Drugs
  38. Effect of Small-molecule GSK3 Antagonist on Differentiation of Rat Dental Pulp Cells into Odontoblasts
    Yoshiko Murakami Masuda, Hiroshi Sakagami, Satoshi Yokose, Nobuyuki Udagawa · 2020 · In Vivo
  39. Rare Tauopathies
    Farwa Ali, Keith A. Josephs · 2019 · Seminars in Neurology
  40. Toward Biology-Driven Diagnosis of Atypical Parkinsonian Disorders
    Óscar Arias-Carrión, Elizabeth Romero-Gutiérrez, Emmanuel Ortega‐Robles · 2025 · NeuroSci
  41. New Insights Into Genetic Right Ventricular Cardiomyopathies
    Marta Garcia-Montero, Yehia Fanous, Andrew David Krahn, Brianna Davies, Julia Cadrin‐Tourigny, Jason D. Roberts · 2025 · Canadian Journal of Cardiology
  42. Evaluation of Tideglusib as a Disease Modifying Therapy in Murine Models of Arrhythmogenic Cardiomyopathy
    Malhotra, Nipun, Cavus, Omer, Wallace, Michael J., Bobik, John T., You, Kevin, Takenaka, Sarah S., Abdallah, Danielle, Mohler, Eleanor J., Antwi-Boasiako, Steve, Murphy, Nathaniel P. et al. · 2025 · JACC: Basic to Translational Science
  43. Efficiency of multivariate tests in trials in progressive supranuclear palsy
    Elham Yousefi, Mohamed Gewily, Franz König, Günter U. Höglinger, Franziska Hopfner, Mats O. Karlsson, Robin Ristl, Sonja Zehetmayer, Martin Posch · 2024 · Scientific Reports
  44. A Selective GSK3β Inhibitor, Tideglusib, Decreases Intermittent Access and Binge Ethanol Self‐Administration in C57BL/6J Mice
    Sam Gottlieb, Andrew D. van der Vaart, Annalise Hassan, Douglas Bledsoe, Alanna Morgan, Brennen O'Rourke, Walker D. Rogers, Jennifer T. Wolstenholme, Michael F. Miles · 2025 · Addiction Biology
  45. Progressive supranuclear palsy treatment—A systematic review
    Samah H. Hajjar, James K. Cooper · 2016 · Basal Ganglia
  46. A Novel Neuroprotection Target With Distinct Regulation in Stroke and Alzheimer’s Disease
    Andrea Gamir-Morralla, Celia López‐Menéndez, Miguel Medina, Teresa Iglesias · 2017 · Elsevier eBooks
  47. Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
    Ali Shoeibi, Irene Litvan · 2017 · Expert Opinion on Orphan Drugs
  48. Technological advancements to study cellular signaling pathways in inherited retinal degenerative diseases
    Akanksha Roy, Riet Hilhorst, John P. Groten, François Paquet‐Durand, Tushar Tomar · 2021 · Current Opinion in Pharmacology
  49. Frontotemporal dementia
    Eline Wauters, Kristel Sleegers, Marc Cruts, Christine Van Broeckhoven · 2017 · Elsevier eBooks
  50. Assessing the critical role of ceramide in the pathogenesis of Alzheimer's disease and its clinical significance
    Yi‐Wen Huang, Hua‐Chen Chan, Jing-Yi Khoo, Mei-Lin Chan, Daniel A. Bender, Vinoth Kumar Ponnusamy, Abdel Ali Belaidi, Liang‐Yin Ke · 2025 · Neurochemistry International
  51. Computer-aided Drug Discovery of Epigenetic Modulators in Dual-target Therapy of Multifactorial Diseases
    Slavica Oljačić, Marija Popovic-Nikolic, Brankica Filipić, Žarko Gagić, Katarina M. Nikolic · 2024 · Current Topics in Medicinal Chemistry
  52. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
    Madia Lozupone, Vittorio Dibello, Antonio Daniele, Vincenzo Solfrizzi, Emanuela Resta, Francesco Panza · 2024 · Expert Opinion on Pharmacotherapy
  53. Mature neurons from iPSCs unveil neurodegeneration-related pathways in mucopolysaccharidosis type II: GSK-3β inhibition for therapeutic potential
    Tzu‐Yu Chen, Shuan-Pei Lin, De-Fong Huang, Hsien‐Sung Huang, Feng‐Chiao Tsai, Li-Jen Lee, Hsiang-Yu Lin, Hsiang–Po Huang · 2024 · Cell Death and Disease
  54. Progressive Supranuclear Palsy
    Shashank Agarwal, Rebecca Gilbert · 2019 · StatPearls
  55. An Emerging Role for Megalin as a Regulator of Protein Leak in Acute Lung Injury
    Tomeka L. Suber, Rama K. Mallampalli · 2017 · American Journal of Respiratory Cell and Molecular Biology
  56. A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance
    Tien Dam, Lili Yang, Colin Gillis, Yumeng Li, John T. O'Gorman, Barbara Kolb, Adam L. Boxer, Lawrence I. Golbe, Samantha Budd Haeberlein, On behalf of the AL-108-231, PROSPERA, and 4RTNI investigators · 2025 · Nature Communications
  57. Hyperinsulinemia drives glomerular podocyte injury and albuminuria via a self-perpetuating GSK3β–IRS1 insulin desensitization circuit
    Mengxuan Chen, Yudong Fang, Mingzhuo Zhang, Yan Ge, Shoaib Zahoor Junejo, Rujun Gong · 2026 · Metabolism
  58. Clinical Trial Development in Frontotemporal Lobar Degeneration
    Peter Alexander Ljubenkov, Adam L. Boxer · 2022 · Cambridge University Press eBooks
  59. Harnessing RNA‐Protein Interactions for Therapeutic Interventions
    Khushboo Goel, Ishu Saraogi · 2024 · Chemistry - An Asian Journal
  60. Molecular Pathways in Alzheimer’s Disease and Cognitive Function
    Xu Chen, Meredith C. Reichert, Li Gan · 2016 · Elsevier eBooks
  61. A new step towards targeting tau
    Jean‐Christophe Corvol, Luc Buée · 2019 · The Lancet Neurology
  62. The Effect of Tideglusib Application on Type 1 and Type 3 Collagen Expressions by Human Dental-Pulp Derived Stem Cells: A Preliminary Study
    C Güler, AM Yilmaz, Leyla Kuru, Beyza Özen, Ömer Birkan Ağralı · 2024 · Nigerian Journal of Clinical Practice
  63. Specific Inhibition of GSK-3β by Tideglusib: Potential Therapeutic Target for Neuroblastoma Cancer Stem Cells
    Hisham F. Bahmad, Reda Chalhoub, Hayat Harati, Jolie Bou-Gharios, Farah Ballout, Alissar Monzer, Hiba Msheik, Sahar Assi, Tarek Araji, Mohamad K. Elajami et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  64. Tau protein aggregation: A therapeutic target for neurodegenerative diseases
    Aryan Duggal, Drishti Mahindru, Kirti Baghel, Sanjana Mehrotra, Vijay Kumar Prajapati · 2025 · Advances in protein chemistry and structural biology
  65. Role of GSK-3 Inhibition in Alzheimer’s Disease Therapy
    Hala Algazzawi, Jakleen Ziyad Abujamai, Asim Muhammed Alshanberi, Rukhsana Satar, Shakeel Ahmed Ansari · 2025 · Current Alzheimer Research
  66. Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders
    Joseph J. Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn, Jennifer G. Goldman · 2021 · Elsevier eBooks
  67. Phosphorylation enhanced OTUD3 deubiquitination ARID3A promotes the progress of cholangiocarcinoma
    Deng‐Yong Zhang, Yan Yu Zhu, Shuoshuo Ma, Chen-yang Xu, Zhong-Lin Wang, Hui Wang, Sihua Liu, Jin Shang, Xiaolun Huang, Prit Benny Malgulwar et al. · 2025 · Oncogene
  68. Therapeutic Modalities Targeting Tau Protein in Alzheimer’s Disease
    Thomas Gabriel Schreiner, Liviu Iacob, Carmen Vasilache, Oliver Daniel Schreiner · 2025 · Journal of dementia and Alzheimer's disease
  69. The Differentiation of Progressive Supranuclear Palsy
    Nicholas J. Cordato, Glenda Margaret Halliday · 2015 · Neurodegenerative Disease Management
  70. Chemical Modulators of Protein Misfolding, Neurodegeneration and Tau
    Pierfausto Seneci · 2015 · Elsevier eBooks
  71. Frontotemporal lobar degeneration
    Boram Kim, Ashley Viera-Ortiz, Jessica M. Phan, David John Irwin, Edward B. Lee · 2022 · Elsevier eBooks
  72. Diagnoses of corticobasal syndrome and corticobasal degeneration
    Takayoshi Shimohata, Ikuko Aiba, Masatoyo Nishizawa · 2016 · Rinsho Shinkeigaku
  73. Neuroprotektive Therapien bei Tauopathien
    Gesine Respondek, Lea Krey, Meret Koroni Huber, Henning Pflugrad, Florian Wegner, Günter U. Höglinger · 2021 · Der Nervenarzt
  74. Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy
    Alison Taylor, Christopher E. Rudd · 2019 · Journal of Immunological Sciences
  75. Progressive Supranuclear Palsy
    Huw R. Morris · 2017 · Neurodegeneration
  76. Combined Assessment of Function and Survival to Demonstrate the Effect of Treatment on Progressive Supranuclear Palsy
    Massimiliano Germani, Irene Rebollo Mesa, Tim J. Buchanan, Steven De Bruyn, Teresa Gasalla, Hans Lieve G. Van Tricht, Colin Ewen, Lawrence I. Golbe, Adam L. Boxer, Günter U. Höglinger · 2024 · Movement Disorders
  77. Molecular docking and simulation studies of FDA approved drugs targeting Allosteric inhibition of Glycogen synthase kinase-3β
    Karkala Sreedhara Ranganath Pai · 2026 · Jordan Journal of Pharmaceutical Sciences
  78. Neuroprotection trial design in progressive supranuclear palsy: challenges and solutions
    Lawrence I. Golbe, Ronald G. Thomas · 2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  79. Developments in the design and therapeutic applications of GSK3β inhibitors
    Safa Daoud, Mutasem O. Taha · 2026 · Future Medicinal Chemistry
  80. Tau Phosphorylation as a Therapeutic Target in Alzheimer’s Disease
    Miguel Medina, Jesús Ávila · 2016 · Elsevier eBooks
  81. Pharmacologictherapy for FTD and related disorders
    Richard M. Tsai, Adam L. Boxer · 2015 · Cambridge University Press eBooks
  82. Progressive supranuclear palsy
    Н. В. Федорова, Бриль Екатерина Витальевна, T.K. Kulua, A. Mikhaylova · 2021 · S S Korsakov Journal of Neurology and Psychiatry
  83. GSK-3β inhibition with antiplasmodial activities from the extracts of actinomycetes isolated from Malaysian forest soil
    Fauze Mahmud, Ali, A. H., Dg. Nur Azierah Fachyuni Abdul Aziz, Salahaudin Maili, Mary Jembun, Suhaini Binti Sudi, Nursuhana Dahari, Ning-Sheng Lai, Siew‐Eng How, Jualang Azlan Gansau et al. · 2023 · Malaysian Journal of Microbiology
  84. Corticobasal Degeneration and Corticobasal Syndrome
    Gerard Saranza, Melissa J. Armstrong, Anthony Edward Lang · 2025 · Cambridge University Press eBooks
  85. La paralysie supranucléaire progressive
    Alexandre Eusébio · 2015 · Pratique Neurologique - FMC
  86. INIBIDORES DA GSK-3: UMA NOVA ESTRATÉGIA PARA A REGENERAÇÃO DENTAL
    Caroline Orejana Ghizzi Bentos, Airton Vicente Pereira · 2017 · Iniciação Científica Cesumar
  87. Reply to: “Brief Clinical Rating Scales Should Not Be Overlooked”
    Gesine Respondek, Ines Piot, Günter U. Höglinger · 2020 · Movement Disorders
  88. Update on the Diagnosis and Management of Progressive Supranuclear Palsy
    Alícia Garrido, Dolores Vilas, EDUARDO S. TOLOSA · 2016 · Current Geriatrics Reports
  89. Treatment
    Bradford Clark Dickerson · 2015 · Cambridge University Press eBooks
  90. Aktuelle Therapiestudien im Bereich der atypischen Parkinson Syndrome
    Kerstin Schweyer, Johannes Levin, Günter U. Höglinger · 2018 · Fortschritte der Neurologie · Psychiatrie
  91. Störungen der Basalganglienfunktion
    Christiana Franke, Alexander Storch · 2019 · Elsevier eBooks
  92. Parkinson-Plus Syndromes
    Cameron Miller‐Patterson, Kathryn E. Krobot, Edward A. Burton, Libby J. Smith · 2020 · Springer eBooks
  93. Identification of Novel GSK-3β Inhibitors through Docking Based Virtual Screening and Biological Evaluation
    Xu M, Gao Sy, Zeng YX, Gao JR, Qiang Ye, Gang Cheng, Li Xu, Li J, Zhou Yb · 2021 · Austin Journal of Cancer and Clinical Research
  94. Monitoring of Stem Cell Differentiation by Glycogen Synthesis Kinase-3 (GSK-3) Inhibitors in Induced Palatal Ulcer in Rabbits
    Heba Abdelrazak Abdelfatah, Mostafa Abdel Ghani, Heba Adawy · 2021 · Al-Azhar Dental Journal for Girls
  95. Reply to: “Application of the mPSPRS to the Salerno Cohort”
    Gesine Respondek, Günter U. Höglinger · 2021 · Movement Disorders
  96. Progressive Supranuclear Palsy
    María Stamelou, Wolfgang H. Oertel · 2017 · Springer eBooks
  97. Putative role of cGMP-dependent protein kinase G in inherited retinal degeneration: modulators and biomarkers
    Akanksha Roy · 2022
  98. Acceleration of GSK3α/β Exocytosis Inhibits Tauopathy
    Da‐Long He, Xiaoyu Zhang, Jing‐Yang Su, Qi Zhang, Lingxiao Zhao, Ting-Yao Wu, Hang Ren, Rong‐Jun Jia, Xian‐Fang Lei, Wen‐Jia Hou et al. · 2024 · SSRN Electronic Journal
  99. Cancer prevalence after exposure to Wnt-activating drugs: a systematic review
    Ahmed Alkashaf, Natalia Smith‐Cortinez, Georgina E Fenton, Sebastian Thomas Bok, Robert Jan Stokroos, Inge Stegeman, Louise V. Straatman · 2025 · BMJ Open
  100. Literaturverzeichnis
    2022 · Elsevier eBooks